2,4-dioxo-3-[4-(2H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester | 448965-55-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2,4-dioxo-3-[4-(2H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester
• 英文别名: (3-methoxyphenyl)methyl 2,4-dioxo-3-[[4-(2H-tetrazol-5-yl)phenyl]methyl]-1H-thieno[2,3-d]pyrimidine-6-carboxylate
• CAS: 448965-55-7
• 化学式: C₂₃H₁₈N₆O₅S
• 分子量: 490.499
• InChiKey: DMYTZNKHTBGHMB-UHFFFAOYSA-N

物化性质

• 密度：
  1.486±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  168
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  3-(4-cyano-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester 、 三正丁基叠氮化锡 以 1,4-二氧六环 为溶剂， 以7%的产率得到2,4-dioxo-3-[4-(2H-tetrazol-5-yl)-benzyl]-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 3-methoxy-benzyl ester
  参考文献：
  名称：

  [EN] MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR IDENTIFICATION OF LEAD COMPOUNDS
  [FR] INHIBITEURS DE METALLOPROTEINASE MATRICIELLE ET PROCEDES D'IDENTIFICATION DE COMPOSES CHEFS DE FILE

  摘要：

  公开号：

  WO2004014381A2

文献信息

• Fused pyrimidinone matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20030004172A1

  公开（公告）日：2003-01-02

  Selective MMP-13 inhibitors are fused pyrimidinones of the formula 1 or a pharmaceutically acceptable salt thereof, wherein: W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical 2 X is O, S, SO, SO 2 , NR 5 , or CH 2 ; 3 B is O or NR 5 ; or A and B are taken together to form —C≡C—; R 1 , R 4 , and R 5 are hydrogen, alkyl, alkenyl, alkynyl, (CH 2 ) n aryl, (CH 2 ) n cycloalkyl, C 1 -C 6 alkanoyl, or (CH 2 ) n heteroaryl; R 2 and R 3 are hydrogen, alkyl, alkenyl, alkynyl CN, NO 2 , NR 4 R 5 , (CH 2 ) n cycloalkyl, (CH 2 ) n aryl, or (CH 2 ) n heteroaryl; R 2 may further be halo; n is an integer of from 0 to 5; and R 4 and R 5 when taken together with a nitrogen to which they are both attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted; with the proviso that R 1 and R 3 are not both selected from hydrogen and C 1 -C 6 alkyl.

  选择性MMP-13抑制剂是具有以下结构的嘧啶酮类化合物或其药用盐： 其中： W与其连接的碳原子一起形成一个5元环二自由基； X为O、S、SO、SO2、NR5或CH2； B为O或NR5； 或A和B结合形成—C≡C—； R1、R4和R5为氢、烷基、烯基、炔基、( )n芳基、( )n环烷基、C1-C6烷酰基或( )n杂环芳基； R2和R3为氢、烷基、烯基、炔基、CN、NO2、NR4R5、( )n环烷基、( )n芳基或( )n杂环芳基；R2还可以是卤素； n为0到5的整数； R4和R5与它们都连接的氮一起形成含碳原子且可选择含有O、S或N的3-8元环，可以是取代或未取代的； 但要注意R1和R3不同时选择自氢和C1-C6烷基。
• Matrix metalloproteinase inhibitors and methods for identification of lead compounds
  申请人：——

  公开号：US20040171543A1

  公开（公告）日：2004-09-02

  The invention relates to compounds that are selective inhibitors of matrix metalloproteinases, to pharmaceutical compositions containing them and to their use in the prevention and/or treatment of MMP-associated diseases. The invention also relates to methods for identification of lead compounds that are selective inhibitors of matrix metalloproteinases. The compounds have the properties that they: (a) bind allosterically to a matrix metalloproteinase or small group of metallic metalloproteinases; (b) bind into at least the S1′ pocket, at least the S1″ pocket (as defined) or at least the S1′ pocket and the S1″ pocket of said matrix metalloproteinase; and (c) exhibit selectivity for a matrix metalloproteinase or group of matrix metalloproteinases other than MMP-13.

  本发明涉及选择性抑制基质金属蛋白酶的化合物，包括含有它们的药物组成物，以及它们在预防和/或治疗与MMP相关的疾病中的应用。本发明还涉及识别选择性抑制基质金属蛋白酶的先导化合物的方法。这些化合物具有以下特性：(a)与基质金属蛋白酶或少量金属金属蛋白酶发生异构作用；(b)至少结合于所述基质金属蛋白酶的S1'口袋、至少结合于S1"口袋（如定义所述）或至少结合于所述基质金属蛋白酶的S1'口袋和S1"口袋；以及(c)表现出选择性，对MMP-13以外的基质金属蛋白酶或基质金属蛋白酶组具有选择性。
• [EN] MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR IDENTIFICATION OF LEAD COMPOUNDS<br/>[FR] INHIBITEURS DE METALLOPROTEINASES MATRICIELLES ET PROCEDES D'IDENTIFICATION DE COMPOSES DE PLOMB
  申请人：WARNER LAMBERT CO

  公开号：WO2004014867A2

  公开（公告）日：2004-02-19